Mr. Richman brings experience in investing in and operating early stage biotech companies. He was involved with the development and launch of several orphan drugs including CytoGam®, Synagis®, Cinryzeâ, Ethyolâ, Respigamâ, and others and has decades of experience at PharmAthene, MedImmune and Tyrogenex. Currently, Mr. Richman is the interim chief executive officer of LabConnect, Inc., a provider of global central laboratory services, a position he has held since November 2018. Mr. Richman was previously a venture partner at Brace Pharma Capital, a life science venture capital firm, from January 2016 to September 2018 and is involved with several private and public biotechnology companies. He served as chief executive officer of Tyrogenex Inc., a biopharmaceutical company, from 2016 to 2018. Mr. Richman served as the president and chief executive officer of PharmAthene, Inc., subsequently acquired by Altimmune, Inc., between October 2010 and March 2015. He also served on PharmAthene’s board of directors, when the company was listed on the NYSE, from 2010 to 2017. Prior to joining PharmAthene, Mr. Richman was a member of the founding team of MedImmune, where he held various commercial and strategic positions, including director of international commercialization. In addition, he has served as a member of numerous boards of directors. Mr. Richman currently serves as a director of Adma Biologics, Inc. (Nasdaq: ADMA), including audit, compensation and governance and nominating committees; Variant Pharmaceuticals, Inc.; NovelStem International Corp. (OTCMKTS: NSTM); and LabConnect, Inc. where he serves as the chairman of the board. Mr. Richman has also served as a director of Lev Pharmaceuticals, Inc. and as chairman of its commercialization committee, and served as a director of American Bank Incorporated (acquired by Viropharma). Mr. Richman received a B.S. in Biomedical Science from the Sophie Davis School of Biomedical Education (CUNY Medical School) and a M.B.A. from the American Graduate School of International Management.
What is Eric I. Richman's net worth?
The estimated net worth of Eric I. Richman is at least $91,663.91 as of May 25th, 2022. Mr. Richman owns 217,729 shares of NeuBase Therapeutics stock worth more than $91,664 as of April 24th. This net worth evaluation does not reflect any other investments that Mr. Richman may own. Learn More about Eric I. Richman's net worth.
How do I contact Eric I. Richman?
Has Eric I. Richman been buying or selling shares of NeuBase Therapeutics?
Eric I. Richman has not been actively trading shares of NeuBase Therapeutics during the last ninety days. Most recently, on Thursday, March 3rd, Eric I. Richman bought 65 shares of NeuBase Therapeutics stock. The stock was acquired at an average cost of $34.40 per share, with a total value of $2,236.00. Learn More on Eric I. Richman's trading history.
Who are NeuBase Therapeutics' active insiders?
Are insiders buying or selling shares of NeuBase Therapeutics?
In the last twelve months, NeuBase Therapeutics insiders bought shares 1 times. They purchased a total of 61,076 shares worth more than $59,854.48. In the last twelve months, insiders at the sold shares 3 times. They sold a total of 207,336 shares worth more than $325,510.56. The most recent insider tranaction occured on September, 14th when Major Shareholder Corp Symetryx sold 129,108 shares worth more than $185,915.52. Insiders at NeuBase Therapeutics own 13.9% of the company.
Learn More about insider trades at NeuBase Therapeutics. Information on this page was last updated on 9/14/2023.
